Download PDF
Thromb Haemost 1995; 74(05): 1361-1367
DOI: 10.1055/s-0038-1649940
Original Article
Animal Models
Schattauer GmbH Stuttgart

Induction of Thrombosis in a Mouse Model by IgG, IgM and IgA Immunoglobulins from Patients with the Antiphospholipid Syndrome

Silva S Pierangeli
1   The Antiphospholipid Standardization Laboratory, Louisville, KY, USA
,
Xiao Wei Liu
2   The Department of Medicine, Division of Rheumatology, Louisville, KV, USA
,
John H Barker
3   The Department of Surgery, Louisville, KY, USA
,
Gary Anderson
4   The Department of Physiology, Louisville, KY, USA
,
E Nigel Harris
5   The Division of Rheumatology,Department of Medicine, Louisville, KY, USA
› Author Affiliations
Further Information

Publication History

Received 17 May 1995

Accepted after revision14 July 1995

Publication Date:
10 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Antiphospholipid syndrome is a disorder of recurrent thrombosis and pregnancy losses associated with production of anticardiolipin antibodies and lupus anticoagulant positivity. Recently, we have adapted a mouse model of induced venous thrombosis to study the role of autoantibodies in thrombus formation. To determine whether immunoglobulins from patients with the antiphospholipid syndrome play a role in thrombosis, we injected groups of CDI mice either with immunoglobulins purified from seven patients with the antiphospholipid syndrome (nine preparations studied: four IgG, three IgM and two IgA) or with immunoglobulins of the same isotype from healthy controls. Seventy- two h after injection, a non-occlusive thrombus was induced in the femoral veins of experimental mice by a pinch injury; the thrombus areas as well as times of formation and disappearance of the thrombi were measured. Eight of the nine antiphospholipid syndrome immunoglobulin preparations caused a significant increase in mean thrombus area and a significant delay in mean thrombus disappearance time as compared with normal controls. To determine whether anticardiolipin antibodies might be involved, separate groups of mice were injected with affinity-purified IgG (n = 2) or IgM (n = 2) anticardiolipin antibodies or with normal immunoglobulins of the same isotype, and the effects on thrombus formation compared. Mean thrombus area and mean disappearance times were again significantly increased in all four groups injected with affinity-purified antibodies. This is the first study to show that anticardiolipin antibodies of IgG, IgM and IgA isotypes may play a role in thrombosis in vivo.

 

  • References

  • 1 Harris EN, Gharavi AE, Hughes GRV. Anti-phospholipid antibodies. Clin Rheum Dis 1985; 11: 591-609
    PubMedGoogle Scholar
  • 2 Derksen RHW M, Kater L. Lupus anticoagulant: revival of an old phenomenon. Clin Exp Rheumatol 1985; 3: 349-357
    PubMedGoogle Scholar
  • 3 Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders: prevalence and clinical significance. Ann Int Med 1990; 12: 682-698
    PubMedGoogle Scholar
  • 4 Sammaritano LR, Gharavi AE, Lockshin MD. Antiphospholipid antibody syndrome: immunologic and clinical aspects. Semin Arth Rheum 1990; 20: 81-96
    CrossrefPubMedGoogle Scholar
  • 5 McNeil HP, Chesterman CN, Krilis SA. Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 1991; 49: 193-280
    PubMedGoogle Scholar
  • 6 Harris EN, Chan JK H, Asherson RA, Aber VR, Gharavi AE, Hughes GRV. Thrombosis, recurrent fetal loss and thrombocytopenia. Predictive value of the anti-cardiolipin antibody test Arch Intern Med 1986; 146: 2153-2156
    CrossrefPubMedGoogle Scholar
  • 7 Ginsburg KS, Liang MH, Newcomer L, Goldhaber SZ, Schur PH, Hennekens CH, Stampler MJ. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992; 117: 997-1002
    CrossrefPubMedGoogle Scholar
  • 8 Alving BM, Barr CF, Tank DB. Correlation between lupus anticoagulants and anticardiolipin antibodies in patients with prolonged activated partial thromboplastin times. Am J Med 1990; 88: 112-116
    CrossrefPubMedGoogle Scholar
  • 9 Lockshin MD, Druzin ML, Qamar T. Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibody. Am J Obstet Gynecol 1989; 160: 439-443
    CrossrefPubMedGoogle Scholar
  • 10 Loizou S, Byron MA, Englert HR, Walport MJ, Hughes GR V. Association of quantitative anti-cardiolipin antibody levels with fetal loss. Quart J Med 1988; 68: 525-531
    PubMedGoogle Scholar
  • 11 Shapiro SS, Thiagarajan P. Lupus anticoagulant. Progress in Haemostas Thromb 1982; 6: 263-285
    PubMedGoogle Scholar
  • 12 Triplett DA. Antiphospholipid antibodies and thrombosis. A consequence, coincidence, or cause? Arch Pathol Lab Med 1993; 117: 78-88
    PubMedGoogle Scholar
  • 13 Alving BM. Lupus anticoagulants, anticardiolipin antibodies and the APS. In: Thrombosis and Hemorrhage. Loscalzo J, Schafer A. eds Blackwell Scientific Publications; Boston, MA: 1994. pp 749-765
    Google Scholar
  • 14 Harris EN. Antiphospholipid Antibodies and Cardiovascular Disease. In: Atherosclerotic cardiovascular disease, hemostasis, and endothelial function. Francis RB. ed Marcel Dekker, Inc.,; NY, NY: 1992. pp 237-276
    Google Scholar
  • 15 Branch DW, Dudley DJ, Mitchell MD. Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in BABL/c mice: A model for autoimmune fetal loss. Am J Obstet Gynecol 1990; 163: 120
    PubMedGoogle Scholar
  • 16 Blank M, Cohen J, Toder V, Shoenfeld Y. Induction of antiphospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anticardiolipin antibodies. Proc Natl Acad Sci 1991; 88: 3069-3073
    CrossrefPubMedGoogle Scholar
  • 17 Bakimer R, Fishman P, Blank M, Srednc B, Djaidetti M, Shoenfeld Y. Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody (H-3). J Clin Invest 1992; 89: 1558-1563
    CrossrefPubMedGoogle Scholar
  • 18 Sthoeger ZM, Mozes E, Tartakovsky B. Anti-cardiolipin antibodies induce pregnancy failure by impairing embryonic implantation. Proc Natl Acad Sci (USA) 1993; 90: 6464-6467
    CrossrefPubMedGoogle Scholar
  • 19 Blank M, Tincani A, Shoenfeld Y. Induction of experimental antiphospholipid syndrome in naive mice with purified IgG antiphosphatidylserine antibodies. J Rheumatol 1994; 21: 100-104
    PubMedGoogle Scholar
  • 20 Pierangeli SS, Barker JH, Stikovac D, Anderson G, Ackerman D, Barquinero J, Acland R, Harris EN. Effect of human IgG antiphospholipid antibodies on an in vivo thrombosis model in mice. Thromb Haemost 1994; 71: 670-674
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Harris EN. Syndrome of the Black Swan. Br J Rheumatol 1987; 26: 324-326
    CrossrefPubMedGoogle Scholar
  • 22 Weir DM. Handbook of Experimental Immunology (Vol 1). Blackwell Scientific Publishers; 1973
    Google Scholar
  • 23 Harris EN, Gharavi AE, Tincani A, Chan JK H, Englert H, Mantelli P, Allegro F, Balestrieri G, Hughes GR V. Affinity-purified anti-cardiolipin and anti-DNA antibodies. J Clin Lab Immunol 1986; 16: 1-6
    PubMedGoogle Scholar
  • 24 Pierangeli SS, Goldsmith GH, Kmic S, Harris EN. Differences in functional activity of anticardiolipin antibodies from patients with syphilis and the antiphospholipid syndrome. Infect Immun 1994; 62 (09) 4081-4084
    PubMedGoogle Scholar
  • 25 Harris EN. Annotation. Antiphospholipid Antibodies Br J Haematol 1990; 74: 1-9
    PubMedGoogle Scholar
  • 26 Gharavi AE, Harris EN, Asherson RA, Hughes GR V. Anticardiolipin antibody isotype distribution and phospholipid specificity. Ann Rheum Dis 1987; 46: 41-46
    PubMedGoogle Scholar
  • 27 Harris EN, Pierangeli SS, Birch D. Anticardiolipin wet workshop report: Vth International Symposium on Antiphospholipid Antibodies. Am J Clin Pathol 1994; 101 (05) 616-624
    CrossrefPubMedGoogle Scholar
  • 28 Asherson RA. The catastrophic antiphospholipid syndrome. J Rheumatol 1992; 19: 508-512
    PubMedGoogle Scholar
  • 29 Harris EN, Bos K. An acute disseminated coagulopathy-vasculopathy associated with the Antiphospholipid Syndrome. Arch Intern Med 1991; 151: 231-233
    CrossrefPubMedGoogle Scholar
  • 30 Greisman CG, Thayamparan RS, Goodwin TA, Lockshin MD. Occlusive vasculopathy in systemic lupus erythematosus: association with anticardiolipin antibody. Arch Intern Med 1991; 151: 389-392
    CrossrefPubMedGoogle Scholar
  • 31 Arvieux J, Pouzol P, Roussel B, Jacab MC, Colomb MG. Measurement of antiphospholipid antibodies by ELISA using β2glycoprotein 1 as an antigen. Br J Haematol 81: 568-573
    PubMedGoogle Scholar
  • 32 Galli M, Comfurius P, Maasen C, Heinker HC, deBaets MH, Van-Breda Vriesman PJ C, Barbui T, Zwaal RF A, Bevers EM. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 336: 544-547
    PubMedGoogle Scholar
  • 33 Matsuura E, Igarashi Y, Yasuda T, Triplett DA, Koike T. Anticardiolipin antibodies recognize β2glycoprotein 1 structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994; 179: 457-462
    CrossrefPubMedGoogle Scholar
  • 34 Roubey RA S. Autoantibodies to phospholipid-binding plasma proteins, a new view of lupus anticoagulant and other “antiphospholipid” autoantibodies. Blood 1994; 84: 2854-2867
    PubMedGoogle Scholar
  • 35 Permpikul P, Rao LV M, Rapaport SI. Functional and binding studies of the role of prothrombin and β2glycoprotein 1 in the expression of lupus anticoagulant activity. Blood 1994; 83: 2878-2892
    PubMedGoogle Scholar
  • 36 Oosting JD, Derksen RHW M, Bobbink IW G, Hackeng TM, Bouma BN, de Groot PG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism. Blood 1993; 81: 2618-2625
    PubMedGoogle Scholar
  • 37 Vermylen J, Amout J. Is the antiphospholipid syndrome caused by antibodies directed against physiologically relevant phospholipid-protein complexes. J Lab Clin Med 1992; 120: 10-11
    PubMedGoogle Scholar
  • 38 Lechner K, Pabinger-Fasching I. Lupus anticoagulant and thrombosis. A study of 25 cases and review of the literature Haemost 1985; 15: 254-262
    CrossrefPubMedGoogle Scholar
  • 39 Weidman CE, Wallace DJ, Peter JB. Studies of IgG, IgM and IgA antiphospholipid isotypes in systemic lupus erythematosus. J Rheumatol 1988; 15: 74-79
    PubMedGoogle Scholar
  • 40 Asherson RA, Mackworth-Young CG, Harris EN, Gharavi AE, Hughes GR V. Multiple venous and arterial thrombosis associated with the lupus anticoagulant and antibodies to cardiolipin in the absence of SLE. Rheumatol Int 1985; 5: 91-93
    CrossrefPubMedGoogle Scholar
  • 41 Kalunian KC, Peter JC, Middlekauff HR, Sayre J, Ando DG, Mangotich M, Hahn BH. Clinical significance of a single test for anti-cardiolipin antibodies in patients with systemic lupus erythematosus. Am J Med 1988; 85: 602-608
    CrossrefPubMedGoogle Scholar
  • 42 Vaarala O, Palosuo T, Kleemola M, Aho K. Anticardiolipin response in acute infections. Clin Immunol Immunopathol 1986; 41: 8-15
    CrossrefPubMedGoogle Scholar
  • 43 Zarrabi MH, Zucker S, Miller F, Derman RM. Immunologic and coagulation disorders in chlorpromazine-treated patients. Ann Intern Med 1979; 91: 195-199
    PubMedGoogle Scholar
  • 44 Canoso RT, Zon LI, Groopman JE. Anticardiolipin antibodies associated with HTLV-III infection. Br J Haematol 1987; 65: 495-499
    CrossrefPubMedGoogle Scholar
  • 45 Gharavi AE. Anti-phospholipid syndrome in murine lupus. In: Phospholipid Binding Antibodies. Harris EN, Exner T, Asherson RA. eds CRC Press; Boca Raton, FL: 1991. pp 403-416
    Google Scholar
  • 46 Smith HR, Hansen CL, Rose R, Canoso RT. Autoimmune MRL-1 pr/lpr mice are an animal model for the secondary antiphospholipid syndrome. J Rheumatol 1990; 17: 911-915
    PubMedGoogle Scholar
  • 47 Carreras LO, Vermylen JG. ‘Lupus’ anticoagulant and thrombosis - possible role of inhibition of prostacyclin formation. Thromb Haemost 1982; 48: 28-40
    PubMedGoogle Scholar
  • 48 Branch DW, Rodgers GM. Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: A possible mechanism for thrombosis. Am J Obstet Gynecol 1993; 168: 206-210
    CrossrefPubMedGoogle Scholar
  • 49 Martinuzzo MB, Maclouf J, Carreras LO, Levy-Toledano S. Antiphospholipid antibodies enhance throinbin-indueed platelet activation and thromboxane formation. Thromb Haemost 1993; 70: 667-671
    Article in Thieme ConnectPubMedGoogle Scholar
  • 50 Campbell AL, Pierangeli SS, Wellhausen S, Harris EN. Autoimmune antiphospholipid antibodies enhance activation and aggregation of human platelets in vitro. Thromb Haemost 1995; 73: 529-534
    Article in Thieme ConnectPubMedGoogle Scholar
  • 51 Cariou R, Tobelin G, Bellucci S, Soria J, Soria C, Maclouf j, Caen J. Effect of the lupus anticoagulant on antithrombogenie properties of endothelial cells inhibition of thrombomodulin dependent protein C activation. Thromb Haemost 1985; 60: 54-58
    PubMedGoogle Scholar
  • 52 Marciniak E, Romond ED. Impaired catalytic function of activated protein C: A new in vitro manifestation of lupus anticoagulant. Blood 1989; 74: 2426-2432
    PubMedGoogle Scholar
  • 53 Malia RG, Kitchen S, Greaves M, Preston FE. Inhibition of activated protein C anil its cofactor protein S by antiphospholipid antibodies. Br J Haematol 1990; 76: 101-107
    CrossrefPubMedGoogle Scholar